Valuation: Dermata Therapeutics, Inc.

Market Cap 5.07M 4.46M 4.14M 3.81M 7.14M 491M 7.27M 49.51M 19.31M 239M 19.03M 18.61M 830M P/E 2026 *
-0.57x
P/E 2027 * -0.83x
Enterprise Value 5.07M 4.46M 4.14M 3.81M 7.14M 491M 7.27M 49.51M 19.31M 239M 19.03M 18.61M 830M EV / Sales 2026 *
50.7x
EV / Sales 2027 * 6.76x
Free-Float
75.18%
Yield 2026 *
-
Yield 2027 * -
1 week-1.56%
Current month-2.33%
1 month+2.44%
3 months-0.40%
6 months-41.94%
Current year-45.69%
1 week 1.2
Extreme 1.2
1.33
1 month 1.17
Extreme 1.17
1.52
Current year 1.1
Extreme 1.1
4.66
1 year 1.1
Extreme 1.1
7.33
3 years 1.1
Extreme 1.1
235.21
5 years 1.1
Extreme 1.1
16,679.99
10 years 1.1
Extreme 1.1
16,679.99
Manager TitleAgeSince
Chief Executive Officer 67 2014-12-07
Director of Finance/CFO 48 2021-08-31
Investor Relations Contact - -
Director TitleAgeSince
Chairman 67 2021-03-31
Director/Board Member 77 2014-12-07
Director/Board Member 78 2016-09-19
Date Insider Type Main position Quantity % Market Cap.
6/16/26 Sell

Director

-11 0.0004%
2/17/26 Buy

General Counsel

1,000 0.0353%
1/2/26 Free

Director

2,500 0.0940%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-1.56%-82.37%-99.44% 5.07M
+1.23%+0.35%+51.62%+87.98% 55.92B
+5.09%+6.24%+63.15%+62.06% 56.67B
+0.25%+0.55%-19.67%-15.22% 23.28B
+0.72%-0.05%+3.84%+409.54% 23.28B
-1.38%+4.71%+29.72%-4.51% 20.54B
-0.37%+0.71%+31.36%-31.61% 17.78B
-0.86%+6.09%+33.06%+546.62% 15.9B
-2.54%-8.73%+164.11%+289.45% 14.64B
+1.22%-0.05%+22.58%+182.63% 13.99B
Average +0.32%+0.98%+29.74%+142.75% 24.2B
Weighted average by Cap. +1.28%+3.18%+43.42%+134.06%

Financials

2026 *2027 *
Net sales 100K 87.95K 81.71K 75.15K 141K 9.68M 143K 977K 381K 4.72M 375K 367K 16.39M 750K 660K 613K 564K 1.06M 72.63M 1.08M 7.33M 2.86M 35.43M 2.82M 2.75M 123M
Net income -9.3M -8.18M -7.6M -6.99M -13.11M -901M -13.34M -90.87M -35.45M -439M -34.92M -34.16M -1.52B -9.7M -8.53M -7.93M -7.29M -13.68M -940M -13.92M -94.81M -36.98M -458M -36.43M -35.64M -1.59B
Net Debt - -
Logo Dermata Therapeutics, Inc.
Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases.
Employees
9
Date Price Change Volume
26-07-23 US$1.260 0.00% 18,106
26-07-22 US$1.260 -1.56% 8,265
26-07-21 US$1.280 +0.79% 63,720
26-07-20 US$1.270 -4.51% 16,216
26-07-17 US$1.330 +3.91% 26,171
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.260USD
Average target price
4.000USD
Spread / Average Target
+217.46%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DRMA Stock